Join our daily newsletter At The Bell to receive exclusive market insights
- Imagion Biosystems (IBX) has entered an agreement with Siemens Healthineers to explore the use of MagSense nanoparticles as an MRI contrast agent
- Contrast agents are used to enhance the image and resolution during MRI scans — thus providing a more accurate method for detecting cancer
- Together, the companies will identify specific protocols for using MagSense to monitor cancer through MRI scanning
- Imagion aims to undertake its first clinical study of the MagSense technology in HER2 breast cancer patients
- IBX is up a healthy 18.2 per cent and shares are trading for 2.6 cents each
Imagion Biosystems (IBX) has entered a collaboration agreement with Siemens Healthineers to further explore the use of Imagion’s MagSense nanoparticles.
The collaboration with Siemens, a leading medical technology company, is in line with Imagion’s strategy to develop new uses of the MagSense nanoparticles as an MRI contrast agent.
Contrast agents are used to enhance the image and improve resolution when doing MRI scans. The companies believe the MagSense nanoparticle could be used as a contrast agent to enhance an MR image of specific diseased tissue. By doing so, this will provide a more accurate method of non-invasively detecting cancer.
Together, the companies will identify specific protocols for using MagSense to monitor cancer through MRI scanning.
“The ability to use a targeted contrast agent like ours, in the MRI setting, could transform the way MRI is used to diagnose cancer and other diseases. In entering into this collaboration, we will jointly gain insight into the clinical and commercial potential of our novel technology,” Imagion Executive Chairman Bob Proulx said.
“Imagion’s targeted contrast technology, MagSense, could offer patients a more specific means to monitor cancer with MRI, and we look forward to assisting Imagion in investigating the application of their technology with MRI scanners,” Siemens Head of Collaborations and Research for Australia and New Zealand Dr Kieran O’Brien said.
Imagion Biosystems previously announced its intention to manufacture MagSense for a HER2 breast cancer study and this collaboration further establishes a pathway to commercialise the MagSense technology.
IBX is up a healthy 18.2 per cent and shares are trading for 2.6 cents each at 10:17 am AEST.
